Serge Saxonov - Oct 5, 2021 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role: Chief Executive Officer, Director
Signature: /s/ Eric S. Whitaker, as Attorney-in-Fact
Stock symbol: TXG
Transactions as of: Oct 5, 2021
Transactions value $: -$2,086,521
Form type: 4
Date filed: 10/7/2021, 04:15 PM
Previous filing: Sep 9, 2021
Next filing: Nov 4, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TXG	Class A Common Stock	Options Exercise	$26.2K	+5.21K	+0.58%	$5.04^*	904K	Oct 5, 2021	Direct	F1
transaction	TXG	Class A Common Stock	Options Exercise	$39.7K	+3.46K	+0.38%	$11.48^*	907K	Oct 5, 2021	Direct	F1
transaction	TXG	Class A Common Stock	Sale	-$716K	-5.02K	-0.55%	$142.47	902K	Oct 5, 2021	Direct	F1, F2
transaction	TXG	Class A Common Stock	Sale	-$868K	-6.06K	-0.67%	$143.40	896K	Oct 5, 2021	Direct	F1, F3
transaction	TXG	Class A Common Stock	Sale	-$274K	-1.9K	-0.21%	$144.40	894K	Oct 5, 2021	Direct	F1, F4
transaction	TXG	Class A Common Stock	Sale	-$250K	-1.72K	-0.19%	$145.42	892K	Oct 5, 2021	Direct	F1, F5
transaction	TXG	Class A Common Stock	Sale	-$43.8K	-300	-0.03%	$146.12	892K	Oct 5, 2021	Direct	F1, F6
holding	TXG	Class A Common Stock						4.5K	Oct 5, 2021	See footnote	F7
holding	TXG	Class A Common Stock						90K	Oct 5, 2021	See footnote	F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TXG	Stock Option (right to buy)	Options Exercise	$0	-5.21K	-7.55%	$0.00	63.7K	Oct 5, 2021	Class A Common Stock	5.21K	$5.04	Direct	F1, F9
transaction	TXG	Stock Option (right to buy)	Options Exercise	$0	-3.46K	-5.95%	$0.00	54.7K	Oct 5, 2021	Class A Common Stock	3.46K	$11.48	Direct	F1, F10

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2	This transaction was executed in multiple trades at prices ranging from $141.94 to $142.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3	This transaction was executed in multiple trades at prices ranging from $142.96 to $143.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4	This transaction was executed in multiple trades at prices ranging from $143.96 to $144.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5	This transaction was executed in multiple trades at prices ranging from $144.96 to $145.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6	This transaction was executed in multiple trades at prices ranging from $146.02 to $146.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7	The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F8	The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F9	This option, originally for 250,000 shares, of which 186,260 have been exercised, vested as to 1/48th of the shares on October 1, 2018, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F10	This option, originally for 145,786 shares, of which 91,116 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.